Nickhill Bhakta Discusses Unanswered Questions About Survivors of Childhood Cancer

Larotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system cancers.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The FDA granted elraglusib a rare pediatric disease designation for Ewing sarcoma based on findings from the 1/2 Actuate-1902 trial.

In this episode of "The Vitals," Ellen Miller, MSN, FNP-BC, talks about meeting a patient who realized she wanted to get pregnant after undergoing chemoradiation as a teenager.

The FDA approved blinatumomab for patients 1 month or older with CD19-positive, Philadelphia chromosome–negative, B-cell precursor acute lymphoblastic leukemia.

Selpercatinib was granted accelerated approval from the FDA for patients aged 2 years and older with thyroid cancer or solid tumors with RET mutations.